Objectives: Neopterin, a marker of inflammation and monocyte activation, is found increased in patients with heart failure (HF). This study investigates whether neopterin levels correlate with left ventricular (LV) remodeling and brain natriuretic peptide (BNP), a marker of cardiac stress, in chronic HF (CHF) patients with different severity of disease.
Introduction
Although the neurohormonal mechanisms are known to be critically involved in the development of chronic heart failure (CHF), a state of immune activation with persistent expression of pro-inflammatory cytokines has also been demonstrated to contribute to the exacerbation of HF [1, 2] . Several studies suggest that activated monocytes are involved in the release of inflammation factors that may contribute to progression of cardiac dysfunction [3, 4] and to matrix remodelling in acute myocardial infarction (AMI) [5] . Production of pro-inflammatory cytokines, such as interleukin (IL)-6, IL-8 and tumor necrosis factor alpha (TNF)-α, potentially affecting left ventricular (LV) remodeling [6] , has been also attributed to secretion by mononuclear cells. High circulating levels of chemoattractant of monocytes, such as IL-8, were observed in congestive HF patients [7] and in CHF patients in New York Heart Association (NYHA) class IV [8] .
Neopterin, an aromatic pteridine mainly synthesized by activated monocytes, is a marker of inflammation, immune system activation and an active participant in cardiovascular diseases [9] . Its assessment is proposed as potential tool useful for risk stratification of patients with AMI [10] , for prediction of 1-year LV remodeling in patients with ST-segment elevation AMI [11] , and as independent predictor of HF hospitalization after an acute coronary syndrome [12] . High serum neopterin levels were found in CHF patients with elevated NYHA class [13] and were associated with high rates of cardiac events in HF patients [14] . In patients with critical limb ischemia, the cardiac rhythm disturbances and ischemic electrocardiographic changes were related to inflammatory mediators, specifically to circulating neopterin levels that correlated with echocardiographic signs of congestive HF [15] .
These findings strongly suggest that enhanced activation of the monocyte-macrophage system may play a role in LV remodeling in CHF patients, probably by secretion of pro-inflammatory cytokines. Thus the purposes of this study were: 1) to assess whether neopterin levels were associated with LV remodeling and circulating levels of pro-inflammatory cytokines, and 2) to compare the neopterin levels with NT-pro-Brain natriuretic peptide (NT-proBNP), recognized as cardiac stress marker, in relation to LV dimensions, in CHF patients with different clinical severity of HF.
Materials and methods

Patients
We studied 98 patients with myocardial dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy (IDC), who had been admitted for routine re-evaluation or for treatment of advanced HF at the Cardiovascular Department of Niguarda Hospital from June 2010 to November 2011. None of the patients included in the study had acute myocarditis, primary pulmonary hypertension, irreversible renal or hepatic failure due to hepatic-renal chronic disease, uncontrolled diabetes mellitus, severe peripheral vascular or cerebrovascular disease, coexisting active neoplasia, pregnancy and alcohol/ drug abuse. At the time of enrollment, baseline clinical and cardiac imaging data were collected. Urine and peripheral blood samples were drawn and immediately processed, and plasma and urine aliquots were frozen at − 80°C for measurement of biomarkers.
Nineteen healthy subjects with normal regional and global LV function were enrolled as control group.
The study protocol was approved by the Local Ethics Committee. All subjects gave written informed consent to participate in the study.
Definitions of clinical and instrumental measures
Clinical cardiac derangement was defined according to the NYHA classification provided separately by two attending cardiologists (MF and AV). Full agreement in class definition was attained in all cases. Transthoracic echocardiograms were performed with a Vivid 7 (GE Healthcare, London, United Kingdom) or iE33 (Philips Healthcare, Best, Netherlands); LV end-systolic and end-diastolic volumes (LVESV and LVEDV, respectively) were measured from four-chamber and two-chamber apical views means of Simpson's method. For LV volume analysis, intraobserver and interobserver variability were 6% and 8%, respectively.
Renal function was assessed by estimated glomerular filtration rate (eGFR) using the abbreviated MDRD formula [16] .
Biochemical assays
Blood and urine samples were drawn in the morning in fasting state to determine levels of inflammatory mediators [plasma IL-6, IL-8, soluble intracellular adhesion molecule (sICAM)-1, serum C-reactive protein (CRP), and urine neopterin] and of serum NT-proBNP by technicians unaware of clinical status of patients.
Plasma IL-6, IL-8 and sICAM-1 levels were measured by enzymelinked immunosorbent assays (R&D Systems, Minneapolis, MN-USA).
Serum CRP concentrations were measured using a Roche/Hitachi 917 Analyzer by high-sensitive immuno-nephelometric method (Roche Diagnostic GmbH, Mannheim, Germany).
Urinary neopterin concentrations were measured by an isocratic high-pressure liquid chromatography (HPLC) method and were normalized by urine creatinine concentrations (Neo/Cr). Briefly, urine samples, stored at −20°C were thawed and centrifuged; the surnatant was then adequately diluted with chromatographic mobile phase (15 mM of K 2 HPO 4 , pH 3.0). Neopterin and creatinine levels were measured using a Kontron instrument (pump 422-S, autosampler 465) coupled to a fluorimetric detector (JASCO FP-1520, λ ex =355 nm and at λ em = 450 nm) for neopterin detection and to a UV-VIS detector (BIO-RAD 1706, λ = 240 nm) for creatinine determination. Neopterin and creatinine separations were performed at 50°C on a 5 μm Discovery C18 analytical column (250× 4.6 mm I.D., Supelco, Sigma-Aldrich) at flow rate of 0.9 mL/min. The calibration curves were linear over the range of 0.125-1 μmol/L and of 1.25-10 mmol/L for neopterin and creatinine levels, respectively.
Serum NT-proBNP levels were measured by the ADVIA Centaur assay (Siemens Healthcare Diagnostics).
Intra-assay and inter-assay coefficients of variation (CV) of investigated biomarkers are reported in Table 1 .
Statistical analysis
Data are expressed as median (25th-75th percentile) or frequency (percentage). Categorical variables were compared using the chisquare test or Fisher exact test when appropriate. Continuous variables were compared between groups using Student's t-test or the Mann-Whitney U-test, according to whether variables were normally distributed or not, as tested by the Kolmogorov-Smirnov test. Prospectively CHF patients were distributed into three groups according to the tertile of Neo/Cr levels. Ordinal logistic regression analysis was used to examine the association between neopterin tertiles (dependent variable) and clinical, echocardiographic and inflammatory variables only in HF patients. We established a multivariate ordinal logistic model which included only variables that were significantly related to neopterin (significance level set at p b 0.05). Results are presented as odds ratio (OR), and their 95% confidence interval (CI). A two tailed p b 0.05 was considered statistically significant.
Results
Characteristics findings in patients with LV dysfunction and controls
The population in this study has been described in Table 2 . Briefly an average age of the patients was 56 years, 17% were female. Fifty-six patients (57%) had a diagnosis of post-ischemic LV dysfunction. Nineteen (19%) patients were in NYHA class I, 38 (39%) patients were in NYHA class II, 27 (28%) in class III, and 14 (14%) in class IV. Cardiac volumes were higher in patients compared to healthy subjects. Moreover, forty-two patients (43%) showed LVEDV index (LVEDVi) ≥97 mL/m 2 , reflecting severe grade of LV remodeling [17], as well as NT-proBNP levels were higher in CHF patients than in controls ( Table 2 ). All patients were taking optimal tolerated medical treatment including ACE-inhibitors, β-blockers, diuretics, and statins.
Controls' median age was 50 years (33-61), 6 subjects (32%) were female. All control subjects had a LVEF > 55%. Smoking habit, hypertension, and diabetes mellitus were similarly represented in controls and HF patients, while renal function, evaluated by eGFR, was lower in patients than in controls.
Neo/Cr levels were higher in patients than in controls. The levels of other investigated inflammatory variables were higher in CHF patients compared to controls, with the exception of serum CRP levels, that were similar between groups (Table 2) . Only Neo/Cr levels correlated significantly with LVEDVi values (R = 0.29, p = 0.006).
Neopterin, clinical and echocardiographic variables in CHF patients
Patients were distributed according tertiles of Neo/Cr levels as described in Table 3 . The Neo/Cr levels range from 66 to 155 μmol/mol in the first tertile, from 157 to 225 μmol/mol in the second tertile, and from 226 to 811 μmol/mol in the third tertile. The median Neo/Cr level of patients in the first tertile was comparable to that of controls, while the median Neo/Cr levels of patients in the second and third tertiles were higher with respect to that of controls (p = 0.002 and p b 0.001, respectively).
Increasing Neo/Cr levels were significantly associated with LVEDVi and NT-proBNP (Table 3) , with the highest tertile of Neo/Cr levels seen with the highest LVEDVi and NT-proBNP levels. Patients with severely abnormal LV dimension (LVEDVi ≥ 97 mL/m 2 ) were 8 (25%) in the first tertile, 17 (50%) in the second tertile, and 17 (53%) in the third tertile of Neo/Cr levels (81% of patients with severely abnormal LV dimension were in the second and third tertile). Statin treatment, and the frequencies of male gender and NYHA class I, was significantly decreased according to the increment of Neo/Cr levels, while diuretic treatment was significantly increased according to the increment of Neo/Cr levels by bivariate analysis (Table 3) .
Etiology, cardiovascular risk factors and renal function, assessed by creatinine clearance, were not associated to Neo/Cr levels. 
Neopterin and inflammatory variables in HF patients
Among inflammatory variables, only serum CRP and plasma IL-8 levels increased according to neopterin levels, while sICAM-1 levels were comparable among CHF patients with different neopterin levels ( Table 3) . The IL-6 levels increased according to neopterin levels but only with a trend by bivariate analysis (Table 3) .
Multivariate analysis
All the variables that reached the significance level p b 0.05 were entered into the final multivariable ordinal regression model. The only parameters independently associated with neopterin levels were LVEDVi values (OR 1.014, 95% CI 1.002-1.026, p = 0.024, Fig. 1A ), IL-8 levels (OR 1.353, 95% CI 1.008-1.815, p = 0.044, Fig. 1B) , and male gender (OR 0.257, 95% CI 0.067-0.977; p =0.046).
Discussion
The findings from our study indicate that, in CHF patients characterized from different clinical severity of HF and grade of LV remodeling, higher neopterin levels are independently associated with increased dimensions of cardiac volume, echocardiographically defined by LVEDVi values. Among inflammatory variables, only IL-8 levels resulted associated with neopterin levels in CHF patients.
Neopterin is a marker of macrophage/monocyte activation with a putative physiological role in enhancing macrophage cytotoxicity through its interactions with reactive oxygen, nitrogen, chloride species [18] , and by its influence on myeloperoxidase activity [19] . Neopterin has shown to promote oxidative stress-triggered apoptosis of vascular smooth muscle cells and to promote plaque growth [20] , even suggesting its role in the inflammatory cascade promoting atherogenesis [21, 22] . In isolated perfused rat hearts neopterin infusion favors negative effects on cardiac performance by an enhancement of oxidative stress, as demonstrated by co-treatment with the antioxidant N-acetylcysteine that attenuated the adverse effect of neopterin [23] . Previous study has demonstrated an inverse correlation between neopterin levels and LV ejection fraction in patients with chronic stable angina [24] . In our CHF patients we demonstrate a relationship between urine neopterin levels and LV remodeling, in particular with diastolic enlargement of cardiac volume, independently from etiology and clinical status of HF patients (NYHA class). Furthermore, patients with severely abnormal LV diastolic dimension [17] were greater associated with higher levels of neopterin. In addition, CHF patients with the greatest concentration of circulating neopterin also showed the highest levels of IL-8, a chemokine crucial on monocyte recruitment and attraction on endothelial cells. Therefore the presence of high levels of IL-8 and of LVEDVi, in association with the severity of the levels of neopterin, support a heightened state of immune activation in CHF patients and the pathological role of monocyte on LV remodeling. As observed even in acute coronary syndrome [12] , C-reactive protein and NT-proBNP levels weren't associated with neopterin in our CHF patients. These data support the potential contribution of the determination of neopterin for the monitoring of ventricular remodeling with respect to C-reactive protein, a non-specific inflammatory biomarker, and NT-proBNP, that reflects the wall stress of left ventricle.
Noteworthy, in the HF disease the activation of metalloproteinases (MMPs) and alteration of extracellular matrix components are considered crucial mechanisms involved in cardiac structural changes that deteriorates into a dilated eccentric pattern [2] . An abnormal balance between MMPs activity and their tissue inhibitors, or an increased activity of MMPs, appear to be involved in collagen scaffold degradation, LV dilation, and to compromise cardiac systolic function [25] . Several studies have even suggested that oxidative stress acts properly on MMPs metabolism, favoring progression of cardiac remodeling [26, 27] .
Previous studies have demonstrated that neopterin concentration, in patients at risk for atherosclerosis or with cancer, relates to their antioxidant status [28, 29] . Moreover, neopterin levels have been found to relate with homocysteine, a pro-oxidant aminothiol deleterious for vascular function [30] . Baseline serum neopterin and MMP-9 concentrations are found associated with rapid progression of coronary artery disease in patients with chronic stable angina pectoris [31] . As a matter of fact inducible MMP-9, a crucial MMP involved in LV remodeling, is also expressed in the failing myocardium by infiltrating inflammatory cells, such as monocytes [32] . In addition, in chronic renal failure the dysregulation of MMPs and their inhibitors were found associated to increased synthesis of neopterin [33] . Therefore, the association found between LVEDVi and neopterin levels in CHF patients is suggestive of an involvement of monocyte activation in LV remodeling probably by oxidative stress induced-MMPs activation.
Neopterin monitoring in body fluids provide information on current state of cellular immune response and frequently help to predict progression of several diseases with intensified monocyte/ macrophage activity [18, 34] . In IDC patients, abnormal neopterin levels were associated with the development of progressive HF and death, suggesting that neopterin levels are related to HF severity [35] . Other study reported that plasma levels of neopterin might predict adverse cardiovascular events in patients with coronary artery disease, acute coronary syndromes or severe peripheral artery disease [9] . In keeping with these reports, we provide evidence that neopterin levels are associated to LVEDVi values in CHF patients supporting neopterin determination as useful tool to evaluate the progression of LV remodeling. Moreover, in the present study, neopterin levels were measured in biological samples easily accessible, such as samples of urine, and assessed by a fast and cheap HPLC technique, with a procedure that lasts less than 15 minutes/sample. Therefore, the measurement of neopterin, as inflammatory and oxidative stress marker, may be clinically helpful to ameliorate risk stratification and to follow disease progression in CHF patients.
Study limitations
Failure to ascertain the levels of metalloproteinases is a limitation of the study. The assessment of MMPs levels according to neopterin levels might provide more accurate information on the role of neopterin in LV remodeling. However, circulating levels of MMPs do not always reflect the expression of cardiac MMPs.
Conclusions
In conclusion, an independent association between urine neopterin levels and LV end-diastolic volume values was observed in CHF patients with different HF clinical severity. The increment of IL-8 levels, according with neopterin levels, suggests that monocyte activation is involved in adverse LV remodeling. The clinical utility of neopterin assessment in monitoring HF progression merits evaluation. Long-term evaluation of LV remodeling progression might identify neopterin as useful prognostic indicator.
